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ABSTRACT
Objective: We aimed to assess the efficacy of neoadjuvant chemotherapy followed by surgery 
(NACT+S), and compared the clinical outcome with that of concurrent chemoradiotherapy 
(CCRT) in patients with International Federation of Gynecology and Obstetrics (FIGO) IB–IIB 
cervical cancer.
Methods: We reviewed 85 patients with FIGO IB–IIB cervical cancer who received NACT+S 
between 1989 and 2012, and compared them to 358 control patients who received CCRT. 
The clinical application of NACT was classified based on the following possible therapeutic 
benefits: increasing resectability after NACT by reducing tumor size or negative conversion 
of node metastasis; downstaging adenocarcinoma regarded as relatively radioresistant; and 
preservation of fertility through limited surgery after NACT.
Results: Of 85 patients in the NACT+S group, the pathologic downstaging and complete 
response rates were 68.2% and 22.6%, respectively. Only two young patients underwent 
limited surgery for preservation of fertility. Patients of the NACT+S group were younger, 
less likely to have node metastasis, and demonstrated a higher proportion of FIGO IB cases 
than those of the CCRT group (p≤0.001). The 5-year locoregional control, progression-free 
survival, and overall survival rates in the NACT+S group were 89.7%, 75.6%, and 92.1%, 
respectively, which were not significantly different from the rates of 92.5%, 74%, and 84.9% 
observed in the CCRT group, respectively (p>0.05).
Conclusion: NACT+S has no therapeutic advantages over CCRT, the standard treatment. 
Therefore, NACT+S should be considered only in selected patients through multidisciplinary 
discussion or clinical trial setting.
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Neoadjuvant chemotherapy followed 
by surgery has no therapeutic 
advantages over concurrent 
chemoradiotherapy in International 
Federation of Gynecology and 
Obstetrics stage IB-IIB cervical cancer
INTRODUCTION
Although the incidence of cervical cancer has decreased over several decades, it is the 7th 
most common cancer among Korean women [1]. The current standard treatments for 
International Federation of Gynecology and Obstetrics (FIGO) stage IB–IIB cervical cancer are 
recommended according to disease stages. For most patients presenting with FIGO stage IB–
IIA disease either confined to the cervix or with limited vaginal extension, no differences were 
observed between radiotherapy and surgery in terms of 5-year survival rates, which were 85% 
to 90%. In practice, radical surgery tends to be selected for FIGO stage IB1 and IIA1, while 
concurrent chemoradiotherapy (CCRT) is offered to patients with FIGO stage IB2–IIA2 who 
have bulky tumors larger than 4 cm confined to the cervix. Additionally, CCRT is the standard 
treatment method for patients with FIGO stage IIB, and is the preferred treatment for patients 
with pelvic and/or para-aortic lymph node metastasis, regardless of disease stage [2,3].
After platinum and anthracycline chemotherapy emerged as effective treatments for solid 
tumors in recurrent and metastatic settings in the late 1970s, the clinical application of 
these regimens was extended progressively to both the adjuvant and neoadjuvant settings, 
particularly in head and neck cancer and uterine cervical cancer [4]. Notably, several 
questions persist concerning the use of neoadjuvant chemotherapy (NACT), such as whether 
it is useful, which chemotherapy regimens and intensities are optimal, and precisely which 
patients benefit [5].
Over the last 30 years, NACT for stage IB–IIB cervical cancer has often been used in practice 
by gynecologic oncologists to improve resectability, although evidence that such a goal is 
achievable is scarce [4]. We conducted this retrospective study to explore the clinical efficacy 
of NACT followed by surgery (NACT+S) compared with that of CCRT as a standard arm in 
patients with stage IB–IIB cervical cancer.
MATERIALS AND METHODS
1. Patients
We retrospectively retrieved the data of 85 cervical cancer patients who underwent NACT+S 
at the Yonsei Cancer Center between January 1989 and December 2012. The patients met 
the inclusion criteria of histopathologically confirmed cervical cancer, including squamous 
cell carcinoma, adenocarcinoma, or adenosquamous cell carcinoma; and stage IB to IIB 
according to the FIGO. The patients did not have other malignant diseases, and had not 
received any prior treatment for cervical cancer. At our institution, NACT+S is used for select 
patients with stage IB–IIB cervical cancer per the physician’s discretion as follows: (1) to 
enhance resectability after NACTs, in case of large tumors, vaginal/parametrial invasion, 
or clinically positive node; (2) to completely resect adenocarcinomas that are considered to 
be relatively more radioresistant than squamous cell carcinoma; and (3) for preservation of 
fertility using limited surgical treatment and omitting radiotherapy.
We also reviewed the data of 358 cervical cancer patients who received CCRT as a standard 
treatment under the same eligibility criteria, and used them as a control group to compare 
treatment outcomes between groups.
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2. Treatment
Patients who were treated with NACT+S (n=85) received median 3 (range, 1 to 8) cycles of 
platinum (75 to 100 mg/m2) based chemotherapy 3 weeks prior to surgery. The regimens 
combined with platinum were used as follows: platinum alone (n=12), vincristine (n=44), 
5-fluorouracil (n=7), etoposide (n=14), and others (n=8). After receiving platinum-
based NACT every 3 weeks, radical surgery was performed in 82 patients, while radical 
trachelectomy with lymphadenectomy was performed in two young patients. According to 
institutional policy, adjuvant treatments such as postoperative radiotherapy (PORT) and 
adjuvant chemotherapy were administered to patients with pathologic risk factors including 
lymphovascular invasion (LVI), perineural invasion (PNI), positive margin, and pathologic 
pelvic lymph node metastasis. After NACT+S, adjuvant treatments were administered as 
follows; PORT in 15 patients, adjuvant chemotherapy in 13 patients, and both in seven 
patients. Thirty-five patients treated with adjuvant treatments had pathological risk factors: 
18 had LVI, four had PNI, 13 had positive margin, and 14 had pathologic pelvic lymph 
node metastasis. PORT with a median 50.4 Gy (range, 30 to 70.8 Gy) was administered 
to the pelvis with external beam radiation therapy (EBRT) alone (n=13), EBRT followed by 
intracavitary brachytherapy (ICR; n=6), and ICR alone (n=1). Patients were administered 
adjuvant chemotherapy with platinum alone (n=5), platinum with paclitaxel (n=8), platinum 
with vincristine (n=5), or platinum with other agents (n=2).
Patients treated with CCRT (n=358) received a median external beam irradiation of 45 Gy 
(range, 36 to 50.4 Gy) in 25 fractions (range, 20 to 28) with a midline block at median 36 Gy 
(range, 21 to 45 Gy) followed by a high dose rate ICR of median 30 Gy (range, 21 to 50 Gy) in 
6 to 13 fractions at point A using 60Co or 192Ir as sources. A lymph node boost with a median 
of 9 Gy (range, 3.6 to 14.4 Gy) was performed in patients with lymph node metastases; 
these metastases were assessed using magnetic resonance imaging (MRI) to determine 
lymph node enlargement (diameter ≥1 cm) or fluorine-18–2-fluoro-2-deoxy-d-glucose (FDG) 
positron emission tomography-computed tomography (PET-CT) that evaluated FDG uptake 
greater than that of the liver or similar to that of the brain cortex. Concurrent platinum-
based chemotherapy with a median of 6 cycles (range, 1 to 9) was administered to patients 
once a week for 6 to 8 weeks. The regimens combined with platinum were as follows: none 
(platinum alone; n=214), 5-fluorouracil (n=138), vincristine (n=1), and others (n=5).
3. Treatment outcome assessment
At our institution, pretreatment evaluation of patients with cervical cancer consisted of 
recording medical history, physical examinations, gynecological pelvic examination with 
biopsy, complete blood count, routine blood chemistry, urinalysis, chest radiography, 
intravenous pyelography, cystoscopy, sigmoidoscopy, CT, and pelvic MRI. PET-CT was 
additionally performed if necessary. After completion of therapy, the patients received 
follow-up examinations every 3 months for the first 2 years, then at 6-month intervals for 3 
years, and once every year thereafter. Recurrences involving the cervix, vagina, or parametrial 
tissue were classified as local failure, lymph node recurrence within the pelvis as regional 
failure, and recurrences involving distant organs as distant failure. The primary end point of 
the study was locoregional control (LRC), progression-free survival (PFS), and overall survival 
(OS). Patient survival was defined as follows: (1) LRC was defined as the interval period from 
the end of treatment to the date of locoregional failure; (2) PFS was defined as the interval 
period from the end of treatment to the date of disease progression or recurrence, last follow-
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up, or death; and (3) OS was defined as the interval period from the end of treatment until 
last follow-up or death from any cause. As a secondary end point in the NACT+S group, we 
examined both resectability rate and pathologic response after the procedure.
4. Statistical analysis
We performed the analysis of associations between the clinicopathologic variables and 
treatment groups (NACT+S group vs. CCRT group) by using the chi-square test. LRC, PFS, 
and OS were calculated by using the Kaplan-Meier method, and the differences between the 
possible prognostic factors were compared using the log-rank test. Cox regression models, 
adjusted for possible prognostic factors including age, histopathologic type, tumor size, 
FIGO stage, clinical metastatic lymph node status, and overall treatment time, were fitted to 
evaluate the impact of the treatment groups on LRC, PFS, and OS. A p≤0.05 was considered 
significant in all statistical tests. Statistical analyses in this study were performed with SPSS 
ver. 20.0.0 (IBM Co., Armonk, NY, USA).
RESULTS
1. Baseline characteristics
In the NACT+S group, the median age was 41 years (range, 27 to 62 years). Twenty-nine 
patients in this group (34.1%) had adenocarcinoma/adenosquamous carcinoma (Adenoca/
AdenoSCa), while 56 (65.9%) had squamous cell carcinoma (SCCa). There were significant 
differences between the two treatment groups in distribution of tumor characteristics such as 
age, histopathologic type, FIGO stage, clinical lymph node status, and overall treatment time 
(p≤0.001). The NACT+S group represented younger patients (41 years vs. 54 years), a larger 
proportion of stage FIGO IB patients (58% vs. 15%), and a smaller proportion of stage FIGO 
IIB patients (26% vs. 81%) than the CCRT group. The latter group had more patients with 
clinical node metastasis than the former group (55% vs. 33%, respectively). Median overall 
treatment time was significantly shorter in the CCRT group than in the NACT+S group (61 
days vs. 83 days, respectively). The baseline characteristics of patients are shown in Table 1.
2. Efficacy of NACT+S
Of 85 patients, 58 (68.2%) experienced pathologic downstaging based on surgical specimens. 
Pathologic downstaging was observed in 29 of 48 patients with FIGO IB tumors (60.4%), 11 
of 15 with FIGO IIA tumors (73.3%), and 18 of 22 with FIGO IIB tumors (81.8%). Nineteen 
patients (22.6%) showed pathologic complete response (pCR). Seventy-two patients (84.7%) 
underwent complete resection after NACT, while 13 (15.3%) underwent incomplete resection 
with microscopic residual tumors, including five patients with FIGO IB, one patient with FIGO 
IIA, and seven patients with FIGO IIB stage tumors. Additionally, of 25 patients with clinical 
node metastasis, 18 (72%) showed no tumor cells in lymph node specimens after surgery.
There was no difference observed according to histopathologic subtype, Adenoca/
AdenoSCa vs. SCCa, with respect to pathologic downstaging rate (72% vs. 66%, respectively; 
p=0.552), pCR (21% vs. 23%, respectively; p=0.791), and complete resection rate (90% 
vs. 82%, respectively; p=1.804). All patients underwent radical hysterectomy and pelvic 
lymph node dissection, except two young patients aged 27 and 32 years with no parity who 
responded to NACT with partial response (PR) and underwent radical trachelectomy with 
lymphadenectomy to preserve fertility.
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3. Patterns of failure of NACT+S
Of the 85 women who underwent NACT+S, 13 (15.3%) developed recurrent tumors. The 
detection of PNI after surgery appeared to be significantly correlated with recurrence on 
univariate (p=0.006) and multivariate (p=0.009) analyses among the selected variables 
(Supplementary Tables 1, 2). We observed local failure in five cases, regional failure in 
three cases, and distant failure in eight cases. In patients who did not receive PORT (n=63), 
we found that six (9.5%) had locoregional failure. Of these patients, four had pathologic 
risk factors after NACT+S, such as lymph node metastasis in two cases, no downstaging 
in two cases, positive surgical margin in one case, and PNI/LVI in two cases. In patients 
who received PORT (n=22), two (9%) had locoregional failure. The patterns of failure are 
reported in Fig. 1.
4. Treatment outcomes
The median follow-up time was 62 months (range, 2 to 215 months) for all patients. The 
5-year LRC rates of patients undergoing NACT+S versus CCRT were similar (89.7% vs. 
92.5%, p=0.430) (Fig. 2A). Tumor size was an independent prognostic factor for LRC on both 
univariate (p=0.015) and multivariate (p=0.045) analyses.
At the end of the follow-up period, 381 patients (86%) survived. The 5-year PFS and OS rates 
did not differ between groups. The 5-year PFS rates in NACT+S versus CCRT patients were 
75.6% vs. 74.0%, respectively (p=0.819) (Fig. 2B). Univariate analysis showed that PFS was 
influenced by histopathologic type (p=0.023), tumor size (p=0.005), FIGO stage (p=0.003), 
and lymph node status (p=0.017). Multivariate analysis revealed that histopathologic type 
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Table 1. Baseline characteristics of patients
Variable CCRT (n=358) NACT+S (n=85) p-value
Age (yr) <0.001
Median (range) 54 (25–82) 41 (27–62)
<50 121 (33.8) 65 (76.5)
≥50 237 (66.2) 20 (23.5)
Histopathologic type <0.001
SCCa 320 (89.4) 56 (65.9)
Adenoca/AdenoSCa 38 (10.6) 29 (34.1)
Tumor size (cm) 0.102
Mean±SD 4.1±1.5 3.5±1.4
<4 138 (38.5) 41 (48.2)
≥4 220 (61.5) 44 (51.8)
FIGO stage at diagnosis <0.001
IB 52 (14.5) 48 (56.5)
IIA 14 (3.9) 15 (17.6)
IIB 292 (81.6) 22 (25.9)
Clinical LN status <0.001
Negative 162 (45.2) 60 (70.6)
PLN positive 143 (39.9) 24 (28.2)
PALN positive* 53 (14.8) 1 (1.2)
OTT (day) <0.001
Median (range) 61 (11–148) 83 (26–325)
<65 222 (62.0) 29 (34.1)
≥65 136 (38.0) 56 (65.9)
Values are presented as number (%) unless otherwise indicated.
Adenoca, adenocarcinoma; AdenoSCa, adenosquamous carcinoma; CCRT, concurrent chemoradiotherapy; FIGO, 
International Federation of Gynecology and Obstetrics; LN, lymph node; NACT+S, neoadjuvant chemotherapy 
followed by surgery; OTT, overall treatment time; PALN, para-aortic lymph node; PLN, pelvic lymph node; SCCa, 
squamous cell carcinoma.
*PALN positive with/without PLN positivity.
(p<0.001), tumor size (p=0.015), FIGO stage (p=0.008), and lymph node status (p=0.025) 
were prognostic factors related to PFS (Table 2). There was no significant difference in 
the 5-year OS between the NACT+S and CCRT groups (92.1% vs. 84.9%, p=0.184) (Fig. 2C), 
although the NACT+S group had more favorable characteristics. Clinical FIGO stage was an 
independent prognostic factor of OS on both univariate (p=0.002) and multivariate (p=0.002) 
analyses (Table 3). On the other hand, lymph node status did not show a statistically significant 
difference in OS with respect to total cohorts or individual treatment groups (Fig. 3).
DISCUSSION
Historically, NACT has been used based on the following rationales: (1) systemic 
chemotherapy inhibits distant metastasis by eradicating latent micrometastases, and (2) 
both pCR and surgical complete resection, which are achieved by reducing tumor volume and 
tumor extent after NACT, improve LRC [4,6].
Debates on whether these rationales for NACT apply equally to cervical cancer are 
still ongoing. The dominant pattern of failure of cervical cancer has been known to be 
locoregional recurrence [7]. Distant metastasis is seldom detected in cervical cancer 
patients at initial diagnosis [8]. Therefore, it is more important to control overt locoregional 
disease with upfront radiotherapy rather than to prevent latent micrometastasis with NACT. 
Furthermore, the effect of NACT on downstaging for purposes of enhancing resectability 
appears to be exaggerated [9-12]. Because most cases show residual disease on pathologic 
analysis after NACT+S, most physicians have no choice but to administer adjuvant 
radiotherapy in clinical practice. Finally, patients are subjected to a triple therapy that 
prolongs overall treatment time, which is reported to be a negative prognostic factor with 
respect to local control [13-15].
The present study showed that NACT was administered to patients for three main purposes: 
enhancement of resectability, presence of adenocarcinoma pathology, and preservation of 
fertility. However, it is difficult to conclude that NACT showed an advantage over upfront 
radiotherapy. Additionally, uneven distribution of baseline characteristics was likely to 
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Fig. 1. Patterns of failure in patients treated with neoadjuvant chemotherapy followed by surgery (NACT+S). (A) All patients treated with NACT+S (n=85), (B) 
patients treated with NACT+S without postoperative radiotherapy (PORT; n=63), and (C) patients treated with NACT+S followed by PORT (n=22).
affect treatment outcomes between the NACT+S and CCRT groups. NACT+S administration 
was associated with lower stage and lower lymph node metastasis than CCRT; however, 
no statistically significant differences in terms of LRC, PFS, and OS were found between 
both groups. Ultimately, NACT+S as an investigational treatment did not outweigh CCRT 
as standard treatment with respect to clinical benefits and efficacy, despite the uneven 
distribution of patients in both groups. It is still questionable whether the efficacy of NACT 
as judged by the aforementioned three clinical aspects would be acceptable as a standard 
treatment in clinical practice.
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Fig. 2. (A) Locoregional control, (B) progression-free survival, and (C) overall survival according to treatment group. CCRT, concurrent chemoradiotherapy; 
NACT+S, neoadjuvant chemotherapy followed by surgery.
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Table 2. Univariate and stepwise multivariate Cox regression analyses of predictors for progression-free survival
Variable UVA MVA*
5-Year PFS p-value HR (95% CI) p-value
Age (yr) 0.604
<50 72.5
≥50 75.4
Histopathologic type 0.023 <0.001
SCCa 76.3 Reference
Adenoca/AdenoSCa 62.4 2.396 (1.495–3.840)
Tumor size (cm) 0.005 0.015
<4 81.1 Reference
≥4 69.5 1.648 (1.103–2.462)
FIGO stage at diagnosis 0.003 0.008
IB 85.5 Reference
IIA/B 70.9 2.089 (1.215–3.589)
Clinical LN status 0.017 0.025
Negative 77.6 Reference
Positive 70.9 1.552 (1.057–2.278)
OTT (day) 0.017
<65 78.7
≥65 68.7
Treatment group 0.819
CCRT 74.0
NACT+S 75.6
Adenoca, adenocarcinoma; AdenoSCa, adenosquamous carcinoma; CCRT, concurrent chemoradiotherapy; FIGO, International Federation of Gynecology and 
Obstetrics; HR, hazard ratio; LN, lymph node; MVA, multivariate analysis; NACT+S, neoadjuvant chemotherapy followed by surgery; OTT, overall treatment time; 
PFS, progression-free survival; SCCa, squamous cell carcinoma; UVA, univariate analysis.
*Variables were entered into the multivariate regression model in a stepwise method if p≤0.10 and were removed at any point if p>0.10.
Table 3. Univariate and stepwise multivariate Cox regression analyses of predictors for overall survival
Variable UVA MVA*
5-Year OS p-value HR (95% CI) p-value
Age (yr) 0.624
<50 85.4
≥50 87.1
Histopathologic type 0.231 0.069
SCCa 87.9 Reference
Adenoca/AdenoSCa 78.3 1.782 (0.956–3.323)
Tumor size (cm) 0.075
<4 90.6
≥4 83.3
FIGO stage at diagnosis 0.002 0.002
IB 95.7 Reference
IIA/B 83.8 3.505 (1.563–7.861)
Clinical LN status 0.239
Negative 87.8
Positive 84.7
OTT (day) 0.034 0.101
<65 88.9 Reference
≥65 83.1 1.527 (0.921–2.531)
Treatment group 0.184
CCRT 84.9
NACT+S 92.1
Adenoca, adenocarcinoma; AdenoSCa, adenosquamous carcinoma; CCRT, concurrent chemoradiotherapy; FIGO, International Federation of Gynecology and 
Obstetrics; HR, hazard ratio; LN, lymph node; MVA, multivariate analysis; NACT+S, neoadjuvant chemotherapy followed by surgery; OS, overall survival; OTT, 
overall treatment time; SCCa, squamous cell carcinoma; UVA, univariate analysis.
*Variables were entered into the multivariate regression model in a stepwise method if p≤0.10 and were removed at any point if p>0.10.
To date, NACT+S is not recommended for the treatment of cervical cancer. Some studies 
concluded that NACT showed a high response rate and might be an option for locally 
advanced cervical cancer [16-18]. However, several concerns were raised regarding their 
conclusions. First, the proportion of non-responders defined as stable or progressive based 
on the World Health Organization criteria was consistently reported to be 50% to 80% 
after administering 3 to 6 cycles of NACT [9-11]. Several regimens have been tried, such as 
vincristine, ifosfamide, and even paclitaxel, in addition to platinum. However, no remarkable 
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Fig. 3. Overall survival according to lymph node (LN) status. (A) Total patients (n=443), (B) patients treated with neoadjuvant chemotherapy followed by surgery 
(n=85), and (C) patients treated with concurrent chemoradiotherapy (n=358).
improvements in response were observed in these trials. Instead, treatment-related grade five 
toxicities occurred, as these potent agents were added to induce favorable response. Second, 
most reports suggested that NACT might be a possible option because responders have 
more favorable survival outcomes than non-responders. However, the control group for the 
responders should not be non-responders, but rather a patient group treated with standard 
treatments like CCRT so as to elucidate the effects of delayed effective local treatment. 
Additionally, meta-analysis failed to show the improvement of survival with NACT compared 
to the primary surgery group [19,20]. In the present study, our results did not support the 
hypothesis that the administration of NACT+S was superior to CCRT, although the former 
had more favorable characteristics compared to the latter. We are awaiting the results 
of an ongoing trial by the European Organization for Research and Treatment of Cancer 
Gynecologic Group (EORTC 55994) that is designed to compare NACT+S to CCRT in stage 
IB2–IIB cervical cancer. For the time being, primary CCRT remains the standard treatment 
for patients with locally advanced cervical cancer.
NACT has produced comparable survival outcomes in responder groups, as has been 
demonstrated in several clinical trials. Until now, we have no reliable biomarkers related to the 
efficacy of NACT despite several investigations. If a biomarker is developed and validated in 
clinical trials, NACT+S could be considered as a treatment option in locally advanced cervical 
cancer. Otherwise, NACT+S ought to only be considered cautiously within clinical trials.
A limitation of our study is its retrospective nature. In particular, this study has a selection 
bias regarding the treatment approach, and its two arms are imbalanced. Patients were 
treated with a heterogeneous chemotherapy regimen, which might have affected treatment 
outcomes. The results should therefore be interpreted conservatively.
In conclusion, although NACT+S has been investigated in several settings for decades, 
NACT+S has no therapeutic advantages over CCRT in FIGO stage IB–IIB cervical cancer. 
Therefore, NACT+S should be considered only in selected patients through multidisciplinary 
discussion or clinical trial settings. The upcoming EORTC 55994 trial is expected to answer 
several questions regarding the clinical significance of NACT+S compared to CCRT.
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